Related Experiment Video
Updated: Jul 16, 2025

SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
Published on: November 1, 2019
SUMOylation and DeSUMOylation: Prospective therapeutic targets in cancer
1Kunming University of Science and Technology, Medical School, Kunming 650500, China.
Abstract:
The SUMO family is a type of ubiquitin-like protein modification molecule. Its protein modification mechanism is similar to that of ubiquitination: both involve modifier-activating enzyme E1, conjugating enzyme E2 and substrate-specific ligase E3. However, polyubiquitination can lead to the degradation of substrate proteins, while poly-SUMOylation only leads to the degradation of substrate proteins through the proteasome pathway after being recognized by ubiquitin as a signal factor. There are currently five reported subtypes in the SUMO family, namely SUMO1-5. As a reversible dynamic modification, intracellular sentrin/SUMO-specific proteases (SENPs) mainly regulate the reverse reaction pathway of SUMOylation. The SUMOylation modification system affects the localization, activation and turnover of proteins in cells and participates in regulating most nuclear and extranuclear molecular reactions. Abnormal expression of proteins related to the SUMOylation pathway is commonly observed in tumors, indicating that this pathway is closely related to tumor occurrence, metastasis and invasion. This review mainly discusses the composition of members in the protein family related to SUMOylation pathways, mutual connections between SUMOylation and other post-translational modifications on proteins as well as therapeutic drugs developed based on these pathways.
Insights
The SUMOylation pathway, a protein modification system, impacts cellular processes and is implicated in tumor development. Understanding SUMOylation and its related therapeutic drugs is crucial for cancer research.
Area of Science:
- Molecular Biology
- Biochemistry
- Cell Biology
Background:
- SUMOylation is a ubiquitin-like protein modification involving E1, E2, and E3 enzymes, distinct from ubiquitination's direct protein degradation.
- The SUMO family comprises SUMO1-5 subtypes, with sentrin/SUMO-specific proteases (SENPs) regulating the reverse SUMOylation process.
- SUMOylation influences protein localization, activation, and turnover, affecting numerous cellular reactions.
Purpose of the Study:
- To review the components of the SUMOylation pathway.
- To explore the interplay between SUMOylation and other post-translational modifications.
- To discuss therapeutic strategies targeting the SUMOylation pathway in diseases, particularly cancer.
Main Methods:
- Literature review of SUMOylation pathway members and functions.
- Analysis of SUMOylation's interactions with other post-translational modifications.
- Examination of therapeutic drug development related to SUMOylation.
Main Results:
- SUMOylation pathway proteins are frequently abnormally expressed in tumors.
- SUMOylation is closely linked to tumor occurrence, metastasis, and invasion.
- The SUMOylation system plays a significant role in cellular regulation and disease pathology.
Conclusions:
- The SUMOylation pathway is a critical regulator of cellular processes and a potential target for cancer therapy.
- Further research into SUMOylation, its modifications, and therapeutic interventions is warranted.
- Understanding the complex network of SUMOylation interactions can lead to novel treatment strategies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
MicroRNAs
Abnormal Proliferation
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

